The registration for this conference has ended. RegistrationCenter


Meningococcal disease, specifically serotype B (MnB), is an ongoing problem in this country, particularly in light of recent university outbreaks. The disease can develop from initial symptoms to death within 24 hours, and as many as 20% of survivors have permanent sequelae. Notably, incidence rates are often a misconception due to under-detection and under-reporting. Given how disabling diseases can be that could have been prevented with vaccination, it is essential that healthcare workers delivering vaccinations enhance their standards of care in practice in order to deliver the highest rates of preventative care. The goal of the activity is to improve comprehension and initiate practice changes so as to improve immunization rates for all patients who are currently scheduled for the MnB vaccination.


Sheldon L. Kaplan, MD
Professor of Pediatrics-Administration
Head of Pediatric Infectious Diseases Section
Chief Infectious Diseases Service
Baylor College of Medicine
Head of Department of Pediatrics
Texas Children’s Hospital
Houston, TX, US

Gary Marshall, MD
Professor of Pediatrics, Chief, Division of Pediatric Infectious Diseases
University of Louisville School of Medicine
Louisville, KY

Please click on the following link and complete this short pre-test before participating in the webinar:

Accreditation Information

Target Audience

The target audience includes pediatricians, primary care physicians, OB-GYNs, infectious disease specialists and other clinicians who care for patients who are scheduled to receive the Meningococcal B vaccine

Learning Objectives:

At the conclusion of this activity, participants will be able to (or better able to):

  1. Discuss the epidemiology of MnB in the United States and the profiles of patients at greatest risk for this vaccine-preventable disease.
  2. Describe recent 2015 MnB immunization updates made by the Advisory Committee on Immunization Practices (ACIP) and the rationale behind a category B recommendation.
  3. Examine the mechanism of action, contraindications, and adverse effect profiles of current MnB vaccines.
  4. Given a patient case, discuss practice considerations for administering the MnB vaccine such as documentation, billing, and screening for additional immunizations.
  5. Recognize and respond to the opportunity to counsel and screen expectant mothers for recommended immunizations.

Accreditation Statement:

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAP Accreditation:

This continuing medical education activity has been reviewed by the American Academy of Pediatrics and is acceptable for a maximum of 1.00 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.

Disclosure Policy:

Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.


Sheldon Kaplan, MD, faculty, receives grant/research/clinical trial support from Pfizer, Cubist, Forest Lab. He is a consultant/Advisory Boards for Pfizer and Theravance.

Dr. Marshall is on the advisory board and an invesitagor for GSK, Merck, Novartis, Pfizer and Seqirus. He is a speaker for Pfizer and Sanofi.

Dr. Pelton receives Grant/Research/Clinical Trial Support from Pfizer; Merck and Cempra. He is a Consultant for Pfizer, GSK, Sanofi and Sequiris.

Planning Committee Disclosures:

Elizabeth Drury, Dana Frazier, and Julie White, planning committee members, have no relevant relationships to disclose. Allison Smith, MD, reviewer, has no relevant relationships to disclose. Carol Moloney, RN MSN CPNP, CNE Course Advisor, is a speaker for Sanofi Pasteur..

Lee Wetzler, MD, content contributor, is an advisor for GSK.

Sheldon Kaplan, MD, faculty, receives grant/research/clinical trial support from Pfizer, Cubist, Forest Lab. He is a consultant/Advisory Boards for Pfizer and Theravance.

Estimated Time to Complete:

1 hour

Commercial Support:

This educational activity is supported by an educational grant from GlaxoSmithKline


Please use the following form to register for this conference. You will receive an email confirmation shortly after you complete the registration. Don't forget to add to your whitelist!

If you are unable to register online or did not receive your confirmation email (don't forget to check your Bulk email folder), please contact our Registration Desk at 866-872-5840 (international callers please dial 617-502-2061). You can also contact us by email Send Email

First Name* Company*
Last Name* Address*
Title* City*
Email* State/Province*
Secondary Email Zip*
Profession Country*

*Required field